<DOC>
	<DOCNO>NCT02142400</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled multiple ascend single study . It hypothesise least dose DS-1093a safe tolerable 2-week treatment period result increase reticulocyte count haemoglobin concentration healthy male volunteer</brief_summary>
	<brief_title>Multiple Ascending Dose Study DS-1093 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subject , age 1845 year . A body mass index ( BMI , Quetelet index ) range 18.030.0 Willing use reliable method contraception trial , 4 month afterwards Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily Investigator participate , comply requirement , entire trial . Willingness give write consent participate reading information consent form ( ICF ) , opportunity discuss trial Investigator delegate . Willingness give write consent data enter The Overvolunteering Prevention System . Clinically relevant abnormal medical history , physical finding , electrocardiogram ( ECG ) , laboratory value pretrial screening assessment could interfere objective trial safety volunteer . Presence acute chronic illness history chronic illness ( particularly hypertension , seizure , kidney disease liver disease , include know newly discover Gilbert 's syndrome ) sufficient invalidate volunteer 's participation trial make unnecessarily hazardous . Impaired endocrine , thyroid , hepatic , respiratory renal function , diabetes mellitus , coronary heart disease , history psychotic mental illness . Presence history malignant disease , basal cell carcinoma successfully treat least 5 year ago . Any medical history , opinion Investigator , suggestive significant bleeding coagulation risk . History venous arterial thrombosis embolic disease . History gastric duodenal ulcer . History treatment , use , erythropoiesis stimulating agent ( e.g . EPO ) . Blood pressure ( BP ) heart rate supine position screen examination outside range 90140 mm Hg systolic , 4090 mm Hg diastolic ; heart rate 40100 beats/min . Haemoglobin concentration &lt; 129 g/L , platelet outside normal reference range screen examination , evidence iron deficiency base serum iron ferritin level . Surgery ( e.g . stomach bypass ) medical condition might affect absorption medicine . Presence history significant hypersensitive allergic reaction drug , except penicillin . Use prescription medicine strong inducer inhibitor cytochrome P450 enzymes , 30 day first dose trial medication ; use overthecounter medicine , exception acetaminophen ( paracetamol ) , 7 day first dose trial medication . Participation another clinical trial new chemical entity prescription medicine within previous 3 month , unwilling abstain participate clinical trial study 3 month receipt final dose trial medication . Positive test hepatitis B , hepatitis C , HIV 1 &amp; HIV 2 . Abuse drug alcohol 2 year first dose trial medication . Evidence drug alcohol abuse screening , intake 21 unit alcohol weekly . Use tobacco nicotinecontaining product 3 month first dose trial medication . Loss 400 mL blood , donation blood , plasma , platelet , blood component , 3 month trial , unwilling abstain donate study 3 month receipt final dose trial medication . Possibility volunteer cooperate requirement protocol . Objection General Practitioner ( GP ) volunteer enter trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>